Table 1.
Recent clinical trials using anti-TGF-β therapy in fibrotic kidney diseases
| Compound | Target | Company | Phase | Disease | Reference or NCT Identifier |
|---|---|---|---|---|---|
| LY2382770 | TGF-β1 | Eli Lilly | Phase II | Diabetic nephropathy | NCT01113801 |
| Fresolimumab (GC1008) | TGF-β1, 2, 3 | Genzyme | Phase I | Focal segmental glomerulosclerosis | 89 |
| Phase II | NCT01665391 | ||||
| Pirfenidone | TGF-β1, 2, 3 | InterMune | Phase II | Focal segmental glomerulosclerosis, | NCT00001959 11 |
| Phase I/II | Diabetic nephropathy | NCT00063583 79 |
TGF, transforming growth factor.
Reference is shown in bold.